Mod GRF 1-29: A Literature Course on What the Published Studies Report

Mod GRF 1-29 — also written as modified GRF (1-29), tetrasubstituted GRF (1-29), or "CJC-1295 without DAC" — is a synthetic analog of the biologically active first 29 amino acids of growth hormone-releasing hormone (GHRH). This course walks through what the peer-reviewed literature actually contains about that molecule and its close relatives, module by module, and marks clearly where the published record runs out. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

How this course is organised

1. Module 1 — what the compound is, its class, origin and forms.
2. Module 2 — mechanism as described in the literature.
3. Module 3 — reported outcomes, organised by study model and endpoint.
4. Module 4 — adverse events as published.
5. Module 5 — pharmacokinetics where data exist.
6. Module 6 — regulatory and anti-doping status, stated factually.

Each module closes with a short "limits of the evidence" note, because the single most important fact about this molecule is how narrow the human literature is.

Module 1: What Mod GRF 1-29 Is and How It Has Been Studied

GHRH is a hypothalamic releasing hormone. Its first 29 residues retain the activity of the full peptide, and that fragment — sermorelin, or GRF(1-29) — became the template for a family of synthetic analogs. Mod GRF 1-29 is that fragment with amino acid substitutions intended to slow enzymatic breakdown and reduce loss of activity during handling. Analytical chemists have catalogued these synthetic GHRH analogs as a distinct class within doping control, describing the structural modifications that separate one analog from another and the assays developed to distinguish them (PMID 34665524).

The DAC distinction that shapes the whole evidence base

The name "CJC-1295" was originally attached to a version of the modified GRF(1-29) sequence carrying a drug affinity complex (DAC) that binds covalently to circulating albumin. The non-DAC version is the one usually marketed under the label Mod GRF 1-29. This matters for reading the literature: the controlled human trial data most often cited in discussions of Mod GRF 1-29 were generated with the DAC-bearing analog in healthy adults (PMID 16352683), and a follow-up analysis of serum protein changes was likewise performed in normal adult subjects given CJC-1295 (PMID 19386527).

Where it appears in the modern literature

Recent narrative reviews written for orthopaedic and sports medicine audiences place GHRH analogs among the injectable peptides encountered in clinical practice and in the consumer market, alongside compounds with and without regulatory approval (PMID 41476424). A 2026 review of therapeutic peptides in orthopaedics similarly framed this class as an area of interest with applications, challenges and unresolved translational questions (PMID 41490200). Forensic work has also documented how substances of this type circulate through informal online markets, using internet forums as an intelligence source on the doping market (PMID 27710891).

Limits of the evidence

No verified clinical trial in the sources reviewed here tested the non-DAC Mod GRF 1-29 product specifically, under that name, in humans. Statements about "Mod GRF 1-29" therefore rest on chemistry that is shared with, but not identical to, the analog that was actually trialled.

Module 2: Mechanism as Described in the Literature

The mechanism described for GHRH analogs is receptor-mediated and indirect. GHRH binds pituitary GHRH receptors, which stimulates release of endogenous growth hormone (GH); circulating GH in turn drives hepatic production of insulin-like growth factor 1 (IGF-1). In healthy adults, researchers reported that administration of the long-acting GHRH analog CJC-1295 produced sustained elevations in both GH and IGF-1, consistent with this pituitary–liver axis (PMID 16352683). A separate analysis reported that activation of the GH/IGF-1 axis by CJC-1295 was accompanied by measurable changes in the serum protein profile of normal adult subjects, indicating downstream effects beyond the two hormones themselves (PMID 19386527).

A less-quoted preclinical counterpoint

The relationship between GHRH signalling and IGF-1 is not uniformly stimulatory at every tissue. In laboratory work, researchers reported that GHRH and GHRH agonists inhibited hepatic and tumoral secretion of IGF-1, describing a direct tissue-level action distinct from the pituitary pathway (PMID 29983893). That finding is a reminder that "GHRH analog raises IGF-1" is a systemic summary, not a complete description of every compartment.

Why the secretagogue framing is used

Because these molecules act upstream of GH rather than supplying GH itself, reviews classify them as secretagogues. A clinical report in hypogonadal men described growth hormone secretagogue treatment and reported that serum IGF-1 levels rose during treatment, which is the pharmacodynamic signature expected of this mechanism (PMID 28830317).

Limits of the evidence

Mechanistic plausibility is not outcome data. None of the cited mechanistic work established that a hormone change of a given size produced a clinical result in muscle, tendon, bone, fat mass or recovery.

Module 3: Reported Outcomes by Study

The table below summarises the models, endpoints and reported results in the verified literature. Every entry describes what was measured, not what a compound is claimed to do.

What the hormone data showed

In healthy adults, the 2006 trial reported that a single subcutaneous injection of the long-acting GHRH analog CJC-1295 produced several-fold increases in mean growth hormone concentrations and sustained increases in mean IGF-1 concentrations lasting for days rather than hours, and that repeated administration kept IGF-1 above baseline (PMID 16352683). The 2009 serum protein analysis then reported that this axis activation was detectable at the level of circulating proteins in normal adult subjects (PMID 19386527).

What the 2026 reviews concluded about performance endpoints

A 2026 systematic appraisal of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance reported that claims in this space frequently outpace the controlled evidence supporting them (PMID 41966639). A parallel review of peptide supplements in sports medicine likewise described limited high-quality human outcome data for most marketed peptides (PMID 42578445), and a critical review of peptide and peptide-analog drug use in recreational and professional sport described widespread non-medical use occurring well ahead of supporting trials (PMID 41880199).

Limits of the evidence

The measured endpoints in the human studies were hormones and serum proteins — surrogate markers. No cited trial randomised participants to Mod GRF 1-29 and measured strength, body composition, injury recovery or sleep as a primary outcome.

Module 4: Mod GRF 1-29 Side Effects: What Studies Report

Adverse-event data for this specific molecule are thin, and the published record should be read as such. In healthy adults, the 2006 CJC-1295 trial reported that the analog was generally well tolerated, with no serious adverse events attributed to it over the study period (PMID 16352683). That is a small, short-duration safety signal from a single-analog trial, not a long-term safety profile.

What reviews report about the broader risk picture

A 2026 review of approved and unapproved peptide therapies reported that safety data for the unapproved category are sparse, that adverse events are inconsistently captured outside of regulated trials, and that products obtained outside pharmaceutical supply chains introduce additional purity and identity risks (PMID 41966639). A primer written for orthopaedic and sports medicine physicians similarly reported concerns about unregulated sourcing, mislabelling and the absence of pharmacovigilance for injectable peptides marketed direct to consumers (PMID 41476424), and a 2026 review of peptide supplements in sports medicine reported the same pattern of incomplete safety characterisation (PMID 42578445).

Theoretical concerns raised in the literature

Because the mechanism works through the GH/IGF-1 axis, reviewers have flagged sustained IGF-1 elevation as a biologically consequential change whose long-term implications have not been resolved in this population; researchers reported that GHRH agonists also interact directly with tumoral IGF-1 secretion in preclinical models, a line of work that underlines why chronic axis manipulation is treated cautiously (PMID 29983893). Forensic analysis of online doping markets further reported that the products circulating in these channels are not subject to the quality controls that clinical-grade material receives (PMID 27710891).

Limits of the evidence

No cited study followed users of non-DAC Mod GRF 1-29 for months or years, and none reported rates of specific adverse events for that product. Absence of reported harm in a small trial of a related analog is not evidence of long-term safety.

Module 5: Pharmacokinetics Where Data Exist

The most informative pharmacokinetic data in the verified literature belong to the DAC-bearing analog. In healthy adults, researchers reported a prolonged elimination profile measured in days, with IGF-1 elevations persisting well beyond a single administration — the property that gave the compound its "long-acting" description (PMID 16352683). That duration is attributed to albumin binding via the drug affinity complex, a feature the non-DAC form does not have.

Detection as an indirect source of PK information

Anti-doping science has generated much of the remaining analytical data. Reviewers described advances in the detection of synthetic GHRH analogs, including the chromatographic and mass-spectrometric approaches used to identify them and their metabolites in biological matrices (PMID 34665524). Complementary method work reported screening strategies for peptidic drugs in the 2–10 kDa range in doping control blood samples, a window that encompasses GHRH-type analogs (PMID 38716080).

Limits of the evidence

No cited source reported absorption, distribution, half-life or bioavailability figures for the non-DAC Mod GRF 1-29 preparation in humans. Any duration attributed to it in popular discussion does not come from the studies summarised here.

Module 6: Regulatory Status, Stated Factually

Mod GRF 1-29 is not an approved drug product in the United States or the European Union; there is no marketing authorisation, no approved label, and no approved indication for it. Material sold under this name is typically offered as "research use only" chemical, a designation that signals it has not been manufactured, tested or released for human administration. Reviews aimed at clinicians have drawn exactly this line, distinguishing approved peptide medicines from unapproved substances circulating for musculoskeletal and performance purposes (PMID 41966639).

Compounding

In the United States, compounding pharmacies may only use bulk drug substances that meet the statutory conditions set out for compounding; substances that are neither the subject of an approved application nor included on the applicable bulk substances list are outside that pathway, and regulators have evaluated several peptides in this category. Clinical reviews have described the resulting grey market and the challenges it creates for physicians asked about these products (PMID 41476424, PMID 41490200).

Anti-doping status

GHRH analogs fall within the prohibited growth hormone secretagogue category in sport, and detection methods for them are actively maintained; reviewers described assay development specifically aimed at synthetic GHRH analogs (PMID 34665524), while a 2026 critical review reported that peptide and peptide-analog use has become a recognised doping problem across recreational and professional sport and bodybuilding (PMID 41880199).

Limits of the evidence

Regulatory classifications change, differ by country, and are not statements about pharmacology. This section is informational and is not legal advice.

What the Studies Did Not Test

Reading the verified literature end to end, several things are conspicuously absent:

• The exact product. No cited randomised trial administered the non-DAC Mod GRF 1-29 preparation to humans under that name.
• Performance and body-composition outcomes. The human endpoints reported were hormones and serum proteins (PMID 16352683, PMID 19386527), not lean mass, strength, tendon healing or recovery.
• Long-term safety. No cited study followed participants for years or reported cancer, glucose or cardiovascular outcomes for this class in healthy users, a gap the 2026 reviews repeatedly flagged (PMID 41966639, PMID 42578445).
• Combination use. No cited trial evaluated GHRH analogs administered together with other secretagogues or hormones.
• Real-world product quality. Forensic work characterised the market rather than the contents of individual vials (PMID 27710891).

Those gaps are the honest conclusion of this course: the literature supports a clear mechanistic story and a limited set of surrogate hormone findings for a related analog, and it does not support outcome claims for Mod GRF 1-29 itself. This page is educational only and is not medical advice; decisions about any substance belong with a licensed physician.

References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects (Growth Hormone & IGF Research, 2009)
• Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels (American Journal of Men's Health, 2017)
• Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1 (Oncotarget, 2018)
• Advances in the detection of growth hormone releasing hormone synthetic analogs (Drug Testing and Analysis, 2021)
• Probing for peptidic drugs (2-10 kDa) in doping control blood samples (Analytical Science Advances, 2022)
• The study of doping market: How to produce intelligence from Internet forums (Forensic Science International, 2016)
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine (The American Journal of Sports Medicine, 2026)
• A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review (The Journal of Sports Medicine and Physical Fitness, 2026)